Approved MS drug made of random myelin-mimicking peptide chains; modest relapse cut, injection burden.
Safety tier
Avoid
strict bar
Positive
37%
of 24 reports
Per month
Not priced
Rank
#59
of 61 research peptides
At a glance
Onset
Relapse reduction builds over months; the trials measured it at one to two years. Nothing is felt from a dose except site reactions.
Lasts
Continuous treatment; the effect lasts only while it is taken.
Access
Approved drug
Strict case
Prescription immunomodulator for relapsing MS with an FDA boxed warning for anaphylaxis (82 cases, 6 deaths reported to 2024, some years into treatment), plus label warnings for liver injury and skin necrosis. Worth it for MS under a neurologist; not a self-directed peptide.
Best effects
Fewer relapses (about 30% fewer than placebo in trials) · fewer new MRI lesions · not broadly immunosuppressive · usable in pregnancy and breastfeeding
Downsides
Injection-site pain, welts, lumps and bruising · permanent lipoatrophy (dents) at injection sites · immediate post-injection reaction (flushing, chest pain, palpitations, breathlessness; about 16% on the daily dose) · transient chest pain unrelated to injections · daily or three-times-weekly self-injection
Typical use
20 mg subq daily, or 40 mg subq three times a week at least 48 hours apart (the doses are not interchangeable).
Stacked with
Stacked with
Vitamin D: Commonly taken alongside by MS patients on any disease-modifying drug. · Benadryl and Tylenol before injecting: Some users pre-medicate to blunt post-injection reactions; this does not prevent anaphylaxis.
Safety
Watch
Anaphylaxis, including fatal, at any point in treatment (FDA boxed warning, January 2025: 82 worldwide cases, 6 deaths) · Hepatic injury including liver failure and hepatitis with jaundice, days to years after starting (label warning) · Injection-site skin necrosis (postmarketing) · Immune modulation; antibodies to the drug form in most patients (label precaution)
Tier by safety barStrict AvoidBalanced AvoidEvidence only Avoid
Seen harm3 of 3
Mechanism2 of 3
Data gap0 of 3
Silent harm2 of 3
Product0 of 3
Never if
Known hypersensitivity to glatiramer acetate or mannitol (label) · Any previous anaphylaxis on glatiramer acetate, unless another clear cause is identified (boxed warning) · Primary progressive MS as the reason for use (no benefit in the PROMiSe trial)
An antigenic random polymer that deliberately modulates the immune response: drug-reactive IgG antibodies form in most patients, IgG rose to 3x baseline in 80% within 3 months, immune-complex deposition in kidneys was seen in rats and monkeys, and the label flags possible effects on tumour surveillance and infection defences without evidence of either. That is the immune-activation category, not a demonstrated in-vivo oncogenic or organ-damage pathway. Copaxone prescribing information, 5.5 Potential Effects on Immune Response ↗
Anaphylaxis itself is immediate and obvious (alone it would be a 1, since it can first appear years into treatment), but the label's hepatic injury can develop days to years after starting and shows on liver tests before it is felt, and lipoatrophy builds slowly and is permanent. Copaxone prescribing information, 5.4 Lipoatrophy and 5.6 Hepatic Injury ↗
Product 0/3
Bought only as a manufactured, regulated prescription product (Copaxone, Glatopa or other generics) from specialty pharmacies, self-injected subq from prefilled syringes; no grey-market or compounded supply. Product risk is technique (hitting a vessel, poor site rotation), not purity or sterility. Copaxone prescribing information, 2 Dosage and Administration ↗
Split. Long-term users (10-29 years) credit it with stable MRIs and staying mobile, and value its lack of immunosuppression, which also makes it the usual choice around pregnancy and breastfeeding. Against that: near-universal injection-site pain, welts and lumps, permanent fat loss (lipoatrophy) and in some cases skin necrosis; frightening immediate post-injection reactions (chest tightness, flushing, palpitations, 'what I imagine death feels like'), sometimes first appearing after years; and several first-hand anaphylaxis reports needing the ER and epinephrine. Reaction threads were searched on purpose, so bad reactions are over-represented in these 24 reports. Current community and specialist consensus favours starting on higher-efficacy drugs (anti-CD20s) instead. Felt nothing: Two of 24 reports describe new lesions or relapses with no benefit; r/MultipleSclerosis regulars widely call it the least effective DMT..
I had the bad reaction about 6 months into starting it. It's what I imagine death feels like.
Bad reactionImmune · Injection · ~1 year
relapsing MS
Studies
Evidence
Approved drug — FDA-approved for relapsing MS since 1996, EU and worldwide; several placebo-controlled RCTs (n up to 1,404). No benefit on progression in primary progressive MS (PROMiSe, n=943). Remyelination evidence is animal only.
Caveat
Among MS drugs it is one of the lowest-efficacy options, and specialists now often start with high-efficacy drugs; its place today is mainly where its safety profile matters (pregnancy, breastfeeding, people who want to avoid immunosuppression). Remyelination or 'repair' is shown only in mice. Generic and brand versions are interchangeable in the US; some users report more reactions after switching, which has not been shown.
The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.
Report grades
Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.
GlowingPositiveMixedNothingNegativeBad reaction
% positive
The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.
Researcher estimate
No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.
Safety tier
Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.
Safety bar
The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.
Seen harm
Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.
Mechanism
A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.
Data gap
How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.
Silent harm
Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.
Product
The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.
Evidence
The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.
Access
How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.
Price per month
Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.
Dose users report
The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.
Shop trust
Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.
Best value
Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.
Testing
Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.
Added peptide
Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.